Price to FCFE (P/FCFE)
Difficulty: Intermediate
Free Cash Flow to Equity (FCFE)
Eli Lilly & Co., FCFE calculation
USD $ in thousands
12 months ended | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
---|---|---|---|---|---|---|
| Net income (loss) | |||||
| Net noncash charges | |||||
| Other changes in operating assets and liabilities, net of acquisitions and divestitures | |||||
| Net cash provided by operating activities | |||||
| Purchases of property and equipment | |||||
| Disposals of property and equipment | |||||
| Net change in short-term borrowings | |||||
| Proceeds from issuance of long-term debt | |||||
| Repayments of long-term debt | |||||
| Free cash flow to equity (FCFE) |
Item | Description | The company |
---|---|---|
FCFE | Free cash flow to equity is the cash flow available to Eli Lilly & Co.'s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. | Eli Lilly & Co.'s FCFE increased from 2015 to 2016 and from 2016 to 2017. |
Price to FCFE Ratio, Current
Eli Lilly & Co., current P/FCFE calculation, comparison to benchmarks
No. shares of common stock outstanding | |
Selected Financial Data (USD $) | |
Free cash flow to equity (FCFE) (in thousands) | |
FCFE per share | |
Current share price (P) | |
Ratio | |
P/FCFE | |
Benchmarks | |
P/FCFE, Competitors | |
Abbott Laboratories | |
AbbVie Inc. | |
Allergan PLC | |
Amgen Inc. | |
Biogen Inc. | |
Bristol-Myers Squibb Co. | |
Celgene Corp. | |
Gilead Sciences Inc. | |
Johnson & Johnson | |
Merck & Co. Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
P/FCFE, Sector | |
Pharmaceuticals & Biotechnology | |
P/FCFE, Industry | |
Health Care |
If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Eli Lilly & Co., historical P/FCFE calculation, comparison to benchmarks
Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (USD $) | ||||||
| Free cash flow to equity (FCFE) (in thousands)2 | |||||
| FCFE per share4 | |||||
Share price1, 3 | ||||||
Ratio | ||||||
| P/FCFE5 | |||||
Benchmarks | ||||||
P/FCFE, Competitors | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Allergan PLC | ||||||
Amgen Inc. | ||||||
Biogen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Celgene Corp. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
P/FCFE, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
P/FCFE, Industry | ||||||
Health Care |
1 Data adjusted for splits and stock dividends.
3 Close price on the filing date of Eli Lilly & Co.'s Annual Report.
2017 Calculations
4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
5 P/FCFE = Share price ÷ FCFE per share
= ÷ =
Ratio | Description | The company |
---|---|---|
P/FCFE | Price to free cash flow to equity is cash valuation indicator of stockholders' equity. | Eli Lilly & Co.'s P/FCFE ratio declined from 2015 to 2016 and from 2016 to 2017. |